KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity.

Chisom Kanu, Shraddha Shinde, Sujatro Chakladar, Ellen B Dennehy, Terri E Weaver, Jiat Ling Poon, Atul Malhotra

Sleep Med 134 106719

PMID40774158
PMCIDPMC12720398
DOI10.1016/j.sleep.2025.106719
发表日期2025-08-07
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1.:AI 判定为 other;Fig. 2.:森林图/亚组分析图;Fig. 3.:AI 判定为 other;Fig. 4.:AI 判定为 other。
摘要

摘要

AIM: In the phase 3 SURMOUNT-OSA trials, tirzepatide treatment significantly reduced the apnea-hypopnea index (AHI) among people with moderate-to-severe obstructive sleep apnea (OSA) and obesity. We evaluated effects of tirzepatide treatment on sleep disturbance, sleep-related impairment, functioning, health-related quality of life (HRQoL), and OSA symptoms in SURMOUNT-OSA participants. METHODS: SURMOUNT-OSA consisted of two randomized, placebo-controlled trials of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks in participants with moderate-to-severe OSA and obesity. For participants using PAP (Study 2), PAP was withdrawn prior to assessments of polysomnography and patient-reported outcome measures (PROMs). Prespecified PROM endpoints were from baseline to Week 52. Changes in sleep-related impairment, sleep disturbance, excessive daytime sleepiness, functioning, and HRQoL were assessed using analysis of covariance. Categorical shifts in OSA symptom severity were described. RESULTS: At Week 52, compared with placebo, tirzepatide-treated participants reported significantly improved Patient-Reported Outcomes Measurement Information System (PROMIS) Short-Form Sleep-related Impairment 8a scores, PROMIS Short-Form v1.0 Sleep Disturbance 8b scores, Functional Outcomes of Sleep Questionnaire Activity-Level scores, EQ-5D-5L scores, and most domains of the Short-Form 36 Health Survey, Version 2. Tirzepatide treatment was also associated with greater improvements in Patient Global Impression of Status and Patient Global Impression of Change symptom scales compared with placebo. Additionally, Study 1 participants reported significant changes in Epworth Sleepiness Scale scores. CONCLUSION: Results indicate that in addition to objective outcomes of improved AHI, hypoxic burden associated with OSA, and cardiovascular risk factors, people with OSA reported benefits in symptoms, functioning, and HRQoL following tirzepatide treatment. GOV NUMBER: NCT05412004.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1.Fig. 1. Change in patient-reported sleep disturbance and sleep-related impairment assessed by change in PROMIS-SD and PROMIS-SRI scores from baseline to Week 52 Abbreviations: CI, confidence interval; diff, difference; LSM, least squares mean; MTD, maximum tolerated dose, n, total number of patients with non-missing data at that particular timepoint; PROMIS-SRI, Patient-Reported Outcomes Measurement Information System Short-Form Sleep-related Impairment 8a; PROMI Data presented are least-square means derived using analysis of covariance with multiple imputation of missing values. The analysis included the full analysis set for the treatment-regimen estimand. **p-value < 0.01, *p-value < 0.05 versus placebo.
非 KM Figure
Fig. 2.Fig. 2. Forest plot of the treatment differences from baseline to Week 52 for the ESS, FOSQ, EQ-5D-5L, and SF-36 v2 acute form PROMs Abbreviations: CI, confidence interval; diff, difference; EQ-5D-5L, EQ-5D-5 Level; EQ-VAS, EQ -Visual Analog Scale; ESS, Epworth Sleepiness Scale; FOSQ, Functional Outcomes of Sleep Questionnaire; LSM, least squares mean; MTD, maximum tolerated dose; PROM, patient-reported outcome measures; SF-36 v2, Short-Form-36 Health Survey, Version 2; TZP, tirzepatide. Data presented are LSM change differences (95 % CI) for TZP MTD versus placebo derived using analysis of covariance with multiple imputation of missing values. The analysis included the full analysis set for the treatment-regimen estimand. Please refer to the Supplementary figures for the number of participants included in each PROM analysis.
非 KM Figure
Fig. 3.Fig. 3. Shift plots of PGIS scales at Week 52 Abbreviations: MTD, maximum tolerated dose; n, number of participants in the population with baseline and postbaseline value; PGIS-OSA, Patient Global Impression of Status – Obstructive Sleep Apnea; TZP, tirzepatide.
非 KM Figure
Fig. 4.Fig. 4. Shift plots of PGIC scales at Week 52 Abbreviations: MTD, maximum tolerated dose; n, number of participants in the population with baseline and postbaseline value; PGIC-OSA, Patient Global Impression of Change – Obstructive Sleep Apnea; TZP, tirzepatide.
非 KM Figure